PERIOPERATIVE INTRAVITREAL TRIAMCINOLONE IN PHAKOEMULSIFICATION FOR CONCURRENT CLINICALLY SIGNIFICANT DIABETIC MACULAR OEDEMA - Triamcinolone in Phakoemulsification in Diabetic Macular Oedema

Moorfields Eye Hospital NHS Foundation Trust0 个研究点目标入组 56 人开始时间: 2006年10月31日最近更新: 2019年12月10日

试验速览

暂无简介。

•1. Patients with Type 1 or Type 2 diabetes mellitus diagnosed according to the 1999 WHO standard
•2. Patients with cataract sufficient in an eye to either cause visual symptoms such as reduced visual acuity, glare, material index myopia, or monocular polyopia, or sufficient to impair fundus visualisation for macular laser treatment of clinically significant macular edema (CSME) as defined by the Early Treatment Diabetic Retinopathy Study (ETDRS) 14
•3. Patients who have persistent CSMO despite previous laser treatment and have concurrent visual impairment considered partially due to cataract.
•4. Patients who have moderate, severe non proliferative diabetic retinopathy, and treated proliferative diabetic retinopathy as defined by a clinical modification 15 of the ETDRS final retinopathy severity scale 16 .
•5. Optical Coherence Tomography III (OCT) measurements of >300 micron at central subfield of fast macula map pre-operatively at the time of listing.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•1. Patients with no CSME
•2. High-risk proliferative retinopathy as defined by the Diabetic Retinopathy Study (DRS) . Patients in whom high-risk proliferative retinopathy had regressed at least 4 months following appropriate laser treatment were considered eligible.
•3. Diabetes associated with specific genetic syndromes (type A insulin resistance); induced by drugs, chemicals, or endocrinopathies; or secondary to pancreatic tumour or pancreatectomy.
•4. Coexistent ocular disease likely to modify visual acuity, for example age-related macular degeneration, amblyopia, retinal venous occlusion.
•5. Coexistent disease likely to significantly affect retinopathy progression, for example severe carotid occlusive disease, high myopia, glaucoma. Patients with renal dysfunction are however, included in the study, as dictated by the need to recruit sufficient patients with more severe retinopathy, in whom some renal impairment was common.
•6. Patients with coexistent disease likely to respond poorly to side effects of intravitreal triamcinalone including glaucoma, ocular hypertension, steroid responders.
•7. Prior intraocular surgery to either eye.
•8. Complicated cataract surgery.

发起方